During the last session, Aquestive Therapeutics Inc (NASDAQ:AQST)’s traded shares were 2.15 million, with the beta value of the company hitting 2.91. At the end of the trading day, the stock’s price was $3.90, reflecting an intraday loss of -8.88% or -$0.38. The 52-week high for the AQST share is $6.23, that puts it down -59.74 from that peak though still a striking 70.51% gain since the share price plummeted to a 52-week low of $1.15. The company’s market capitalization is $350.88M, and the average trade volume was 2.52 million shares over the past three months.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Aquestive Therapeutics Inc (AQST) registered a -8.88% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.88% in intraday trading to $3.90, hitting a weekly high. The stock’s 5-day price performance is -0.51%, and it has moved by -6.70% in 30 days. Based on these gigs, the overall price performance for the year is 186.76%.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Statistics show that Aquestive Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Aquestive Therapeutics Inc (AQST) shares have gone up 176.60% during the last six months, with a year-to-date growth rate less than the industry average at -176.92% against 10.20. In the rating firms’ projections, revenue will increase 14.60% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 12.26M as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 12.6M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 11.13M and 13.24M respectively. In this case, analysts expect current quarter sales to grow by 10.10% and then drop by -4.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.61%. While earnings are projected to return -185.58% in 2024.
AQST Dividends
Aquestive Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
